Hikma Pharmaceuticals Plc Annual Financial Report and Notice of AGM (2238T)
March 16 2023 - 6:17AM
UK Regulatory
TIDMHIK
RNS Number : 2238T
Hikma Pharmaceuticals Plc
16 March 2023
Hikma Pharmaceuticals PLC
2022 Annual Report and Accounts and Notice of 2023 Annual
General Meeting
Hikma Pharmaceuticals PLC (the "Company") announces that, the
Annual Report and Accounts for the year ended 31 December 2022 (the
"Annual Report") and the Notice of the 2023 Annual General Meeting
(the "Notice of AGM") are today being made available to
shareholders.
The Annual Report and Notice of AGM can be viewed or downloaded
from the Company's website at
www.hikma.com/investors/2022-annual-report/ .
In accordance with Listing Rule 9.6.1 copies of the Annual
Report and Notice of AGM have been submitted to the National
Storage Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Hussein Arkhagha +44 20 7399 2760
Chief Counsel and Company Secretary
16 March 2023
About Hikma
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,700 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSUNARROSUOAAR
(END) Dow Jones Newswires
March 16, 2023 06:17 ET (10:17 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024